Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing’s syndrome.

April 15, 2012

Fleseriu et al. • 2012 • J Clin Endocrinol Metab. 2012;97(6):2039-49.